Cooper's 52-Week-Low Selloff: The Guidance Cut Is Inventory, but the Free Cash Flow Is the Proof

CooperCompanies (COO) did everything a beaten-down stock should hate in one afternoon. Revenue for its fiscal third quarter grew just 1% and missed analysts' estimates, management trimmed fourth-quarter and full-year guidance, and the shares fell about 15% after the close — enough to carry them to a fresh 52-week low the following day, touching $52.49. For a holder, that is a painful print. But the reason the guidance came down matters more than the cut itself.

What actually happened is narrower than the stock's reaction suggests. The shortfall was concentrated in CooperVision, the contact-lens business that supplies most of the company's revenue. And the driver there was a decision by management to drain inventory out of U.S. distributors — deliberately shipping less to middlemen for a couple of quarters so excess stock can work its way through the channel. That is a timing event, not evidence that fewer people are buying contact lenses.

CEO Al White drew the line explicitly on the earnings call. U.S. consumption — the lenses actually sold to wearers rather than parked on distributor shelves — was still growing at a mid-single-digit rate. Management estimated that without the inventory pullback, Americas revenue in the quarter would have grown about 5% instead of falling organically. The gap between what Cooper shipped and what consumers bought is the inventory being worked down, and the company says it expects to be largely through the correction by the end of the fiscal year.

Why the cash flow is the number to watch

Keep that distinction in mind, because it reframes what was otherwise an alarming headline. Revenue was flat-to-down only because of the inventory decision. Meanwhile, the part of the business that actually pays the bills kept improving: the company generated record quarterly free cash flow of $273 million, up 66% from a year earlier, and free cash flow for the year to date reached $528 million, up 86%. Free cash flow is the cash a business produces after it has paid to maintain and grow itself — the money left for dividends, buybacks, and paying down debt — and it is the metric that separates a fad from a real engine.

The other disclosures point the same direction. Cooper ended the quarter with leverage below two times debt to EBITDA — light enough that cash generation feeds back to shareholders rather than creditors. It bought back $339 million of its own stock in the quarter on top of a raised repurchase authorization that now tops out at $3 billion. And management wrapped up a strategic review by deciding to keep CooperSurgical, the fertility and women's-health arm, after concluding the offers on the table didn't reflect the business's worth.

That combination — record cash, low debt, stock buybacks at a deflated price — is the reason the 15% multiple reset reads as interesting rather than scary. At the new low, the stock trades at roughly 12 times the company's forward adjusted earnings guidance of about $4.53 per share, with the company guiding to $600–625 million in free cash flow this fiscal year and more than $2.2 billion cumulative from 2026 through 2028. A medical-device franchise with that cash profile, at a single-digit-adjusted-growth moment that management argues is partly self-inflicted, is the sort of setup where a declining price and an improving cash story can diverge.

The honest bear case

The skeptic deserves a fair hearing, because this is not a risk-free setup, and the market has earned its suspicion. For one thing, this is roughly the fourth guidance cut in about two years — a pattern, not an isolated slip. Organic growth has slowed to low single digits, and management's own fiscal 2026 call now implies only 2–3% growth, down sharply from the 4.5–5.5% it guided to at the start of the year. A low multiple is only meaningful if the cash flow grows into it; if the underlying demand is softer than the inventory story suggests, the reset is just a lower-growth company at a fair price, not a bargain.

The competitive picture is the specific thing to watch. Contact lenses are a competitive round between Cooper, Alcon, and Johnson & Johnson, and CooperVision's Americas organic decline lands right in that fight. CooperSurgical, meanwhile, faces a newly approved non-hormonal IUD competitor to its PARAGARD franchise and carries the weight of a recent fertility litigation settlement. Separately, the company's effective tax rate is scheduled to climb to about 17.5% next year from roughly 15.5%, a small headwind to the earnings the low multiple is built on. None of this is a broken balance sheet — it is a question of whether the growth, not the cash, comes back.

What would prove this either right or wrong

The proof path runs through sell-out demand, not the stock chart. If organic growth re-accelerates toward mid-single digits once the inventory correction clears entering fiscal 2027, the 15% drop becomes the expectations reset the article's setup is hunting for: the market priced the old story while the cash flow kept improving underneath. If instead U.S. consumption decelerates further, or the IUD competition begins showing up in CooperSurgical's numbers, then cheap is cheap for a reason, and the cash won't grow into the diluted multiple.

That is the condition to pin the thesis to. The tape pain — the 52-week low, the downgrades, the 15% slide — is real, but tape pain is not the same as business pain. Whether this becomes an opportunity is a question about cash flow and sell-out growth over the next year, and the company has just handed investors the clearest free-cash-flow proof point it has produced in years. I can be wrong again — if the demand doesn't come back, so is this read. But the setup is a cash-rich business at a reset multiple, with the single most important variable (real demand) stated as intact by the people closest to it.